Swog Cancer Research Network

This study tested two different drug combinations in over 1,300 men with newly diagnosed prostate cancer that had spread. One group received standard hormone therapy plus bicalutamide, the other received hormone therapy plus TAK-700. The main goal was to see which combination hel…

This study tested two different drug combinations in 240 people with advanced colorectal cancer that has a specific genetic change called HER2 amplification. One group received a combination of two targeted antibodies (trastuzumab and pertuzumab), while the other received a stand…

This study tested adding elotuzumab to a standard three-drug regimen for people newly diagnosed with high-risk multiple myeloma, a blood cancer that tends to come back quickly. The goal was to find the safest dose of elotuzumab and see if the combination helps keep the cancer fro…

This study tested whether adding cetuximab to afatinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer compared to afatinib alone. It included 174 newly diagnosed or recurrent patients. The goal was to see if the combination improves survival and del…

This large phase III trial tested whether the drug everolimus, taken for about a year after kidney cancer surgery, could help prevent the cancer from coming back. Over 1,500 patients with intermediate- or high-risk kidney cancer participated. The study compared everolimus to a pl…

This study tested two different treatments for people newly diagnosed with a slow-growing type of lymphoma. Both treatments combined standard chemotherapy with a special antibody that targets cancer cells. The goal was to see which combo helped people live longer without their ca…

This study tested whether adding a third chemotherapy drug (nab-paclitaxel) to the standard two-drug regimen (gemcitabine and cisplatin) helps people with advanced bile duct or gallbladder cancer live longer. The trial enrolled 452 patients with newly diagnosed, advanced disease …

This study tested whether adding the drug ramucirumab to standard chemotherapy (carboplatin and paclitaxel) helps people with advanced thymic cancer that cannot be surgically removed. The trial enrolled 21 adults with incurable thymic cancer. Researchers compared how long the can…

This study tested a drug called isatuximab in 43 people with AL amyloidosis, a rare disease where abnormal proteins build up in organs. The drug is a lab-made antibody that helps the immune system attack the faulty cells making these proteins. The goal was to see if it could lowe…